Beta Thalassemia
15
1
3
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 15 trials
100.0%
+13.5% vs benchmark
7%
1 trials in Phase 3/4
0%
0 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (15)
Association of Micro RNA-155 With Alloimmunization in Transfusion-Dependent Patients
Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia
Evaluating the Effect of N-Acetyl Cysteine and Alpha Lipoic Acid in Patients With Beta Thalassemia
A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia
Stem Cell Transplant in Sickle Cell Disease and Thalassemia
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Evaluation of Heart Status in Patients of Beta Thalassemia Using Echocardiogram
Association of Hb F Level With Clinical Severity of Beta Thalassemia
Genetic Variants Affecting the Clinical Severity of Beta Thalassemia
Effects of Spirulina on Cardiac Functions in Children With Beta Thalassemia Major
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
Genetic Factors Affecting the Severity of Beta Thalassemia
Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia
5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia
Hydroxyurea to Treat Beta-Thalassemia (Cooley's Anemia)